<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="113837">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01621256</url>
  </required_header>
  <id_info>
    <org_study_id>NM-V-101</org_study_id>
    <secondary_id>2012-000066-37</secondary_id>
    <nct_id>NCT01621256</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled Study on Efficacy, Safety and Tolerability of Ancrod in Patients With Sudden Sensorineural Hearing Loss (SSHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordmark Arzneimittel GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinSupport GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MWI Medizinisches Wirtschaftsinstitut GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ProjectPharm s.r.o.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LCR Leading Clinical Research s.r.o.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>X-act Cologne Clinical Research GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordmark Arzneimittel GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ancrod is effective and safe in the
      treatment of sudden sensorineural hearing loss (SSHL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PTA (pure tone audiogram) in the affected ear</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in speech recognition in the affected ear</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient assessment of change in hearing impairment</measure>
    <time_frame>From baseline to Day 8, Day 30 and Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in fibrinogen concentration</measure>
    <time_frame>From baseline to Day 2 and Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in biomarkers</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Hearing Loss</condition>
  <condition>Deafness</condition>
  <condition>Hearing Loss, Sensorineural</condition>
  <condition>Hearing Disorders</condition>
  <condition>Ear Diseases</condition>
  <arm_group>
    <arm_group_label>Ancrod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ancrod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ancrod</intervention_name>
    <description>Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections</description>
    <arm_group_label>Ancrod</arm_group_label>
    <other_name>Viprinex</other_name>
    <other_name>NM-V</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections</description>
    <arm_group_label>Saline solution</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral idiopathic sudden sensorineural hearing loss ≥30 dB

          -  Symmetric hearing prior to onset of SSHL

          -  Enrollment has to be accomplished within 7 days after SSHL onset

        Exclusion Criteria:

          -  Bilateral SSHL

          -  Incomplete recovery after previous SSHL

          -  Previously existing, known retrocochlear hearing loss

          -  Any history of any ear operation or local inflammatory disease in the past one year

          -  History of blunt or penetrating ear trauma, head trauma, barotrauma, or acoustic
             trauma immediately preceding SSHL

          -  History of Meniere's disease, autoimmune hearing loss, radiation-induced hearing
             loss, endolymphatic hydrops.

          -  Treatment with steroids for any reason within the preceding 30 days.

          -  Body weight &gt; 140 kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin Forssmann, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nordmark Arzneimittel GmbH &amp; Co. KG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Canis, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department for Otolaryngology, University Göttingen Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cornelia Breuer</last_name>
    <phone>+49-4122-712-0</phone>
    <email>cornelia.breuer@nordmark-pharma.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen, Georg-August-Universität</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AMEOS Klinikum</name>
      <address>
        <city>Haldensleben</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HNO Zentrum</name>
      <address>
        <city>Landsberg am Lech</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München (LMU)</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>June 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Ear Diseases</mesh_term>
    <mesh_term>Hearing Disorders</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ancrod</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
